Beryl Drugs Limited reported a sharp turnaround in profitability for the first quarter of FY27, with net profit jumping 946% year-on-year to ₹22.08 lakh, driven by a 56% surge in total revenue from operations to ₹75.66 lakh. The Board of Directors approved the unaudited financial results for the quarter ended June 30, 2026, during its meeting held on August 11, 2026, at the company’s registered office in Indore, Madhya Pradesh.

The significant improvement in the bottom line was supported by robust top-line growth, as net sales rose to ₹72.97 lakh from ₹47.94 lakh in the corresponding period of FY26. This revenue expansion helped offset higher cost of materials consumed, which increased to ₹43.40 lakh from ₹22.09 lakh year-on-year. Despite the higher input costs, the company managed to expand its operating profit before tax to ₹26.98 lakh, compared to just ₹6.97 lakh in Q1FY26.

Financial Performance Highlights

The company’s financial statement for the quarter reflects improved operational efficiency and margin expansion. Key metrics include:

Total expenses stood at ₹72.97 lakh, comprising ₹43.40 lakh for materials consumed, ₹6.20 lakh in finance costs, and ₹18.57 lakh in other expenses. Employee benefit expenses remained stable at ₹6.31 lakh. The tax expense for the quarter was ₹4.90 lakh, resulting in the reported net profit of ₹22.08 lakh.

Auditor Review and Compliance

The unaudited financial results were subjected to a limited review by the statutory auditors, Subhash Chand Jain Anurag & Associates. The audit firm issued its review report pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report confirms that nothing has come to their attention to suggest that the financial statements do not disclose the required information or contain material misstatements.

The Board also took on record the limited review report and reaffirmed that the company’s books of accounts are maintained at its registered office in Indore. Sudhir Sethi, Chairman & Director, and Sanjay Sethi, Managing Director, signed off on the resolutions.

What the Numbers Show

The dramatic 946% surge in net profit highlights a strong recovery in Beryl Drugs’ operational performance after a lean period in Q1FY26, where net profit was merely ₹2.11 lakh. The ability to grow revenue by over 56% while maintaining control over employee costs and finance charges suggests improved pricing power or volume growth in its pharmaceutical segment. With earnings per share rising tenfold to ₹0.44, shareholder value creation has accelerated significantly in the opening quarter of the fiscal year.

Beryl Drugs Limited reported on July 20, 2026, that its official website is temporarily unavailable due to an unexpected technical issue. The company confirmed that the disruption is limited to website accessibility and has not impacted its business operations, financial systems, or statutory records.

Upon identifying the problem, Beryl Drugs immediately began coordinating with technical service providers to implement corrective measures. Restoration activities are currently in progress as the company works to resume normal website operations at the earliest.

The intimation was submitted to the BSE in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the applicable provisions of the Companies Act, 2013. The disclosure was signed by Sudhir Sethi, Chairman & Director.

Key Details

The company stated that any material developments regarding the restoration of the website will be communicated to the stock exchange as required under the applicable regulatory framework.